

## Higher

### A strong first quarter


The global healthcare sector<sup>1</sup> rose 2.3 percent in March, compared to a 3.1 percent rally in the global equity markets<sup>2</sup>, led by energy stocks. The broad equity markets rose 8.8 percent in the first quarter, the strongest first quarter since 2019. The rally has been led by communication services, technology, as well as the energy sector. Defensive sectors as well as consumer discretionary stocks underperformed in the first quarter. The healthcare sector returned 7.4 percent in Q1, led by the two largest/highest valued healthcare stocks across the market, Eli Lilly and Novo Nordisk, which rose 33.7 percent and 24.3 percent respectively. Small and mid-cap healthcare stocks continued to underperform the increasingly large-cap concentrated healthcare index. The first quarter was relatively quiet in terms of idiosyncratic/company specific news, whereas style factor returns were unusually impactful. Momentum, sentiment, and size factors had big payoffs in what we experienced as a systematic healthcare tape.

### Fund up 2.1 percent

The Sector Healthcare Value Fund rose 2.1 percent in March<sup>3</sup> and is up 4.0 percent year-to-date. The returns in March were broad based with positive contributions from all segments of the book excluding biotechnology. The top performing holdings were Pfizer, UCB and Medtronic. Single stock losses were modest in size but led by Novartis, Sandoz and Alkermes. The Fund's first quarter absolute returns were led by our medical equipment as well as pharmaceutical holdings and partly offset by losses in our biotechnology holdings. The top performing single stock positions were UCB, GSK, Tenet Healthcare and GE Healthcare. The worst performing single stock positions were Biogen, Eisai, and Incyte. The Fund had a difficult quarter on a relative basis with roughly ¾ of underperformance attributable to not being invested in the obesity stocks, Eli Lilly and Novo Nordisk.

### First quarter; gains and losses

The Fund's outsized wins in UCB, GSK and Tenet were partly offset by losses in the Alzheimer drug companies Biogen and Eisai. We are still optimistic that the Alzheimer drug category, and Leqembi owned by Eisai and Biogen, will develop into a meaningful drug category over time and that both stocks have limited value ascribed to this scenario. Sticking with return laggards was costly in the first quarter as stocks with high sentiment and momentum significantly outperformed as a group. Making sense of stock price reactions to incremental fundamental news was at times challenging in the first quarter, in our view reflecting the systematic market environment.



<sup>1</sup> MSCI World Healthcare Index


<sup>2</sup> MSCI World Net Index

<sup>3</sup> The Fund's month end was March 27<sup>th</sup>, due to bank holidays on March 28<sup>th</sup>-29<sup>th</sup>

## Analysis of Return

Please note: Past performance does not predict future returns

Sector Healthcare Value	Absolute				Relative			March 2024
	A USD	A EUR	A NOK	Index*	A USD	A EUR	A NOK	
NAV	548.53	349.52	3,175.78					
Last Month ***	2.1%	2.1%	2.1%	2.3%	-0.2%	-0.3%	-0.3%	
Year to Date	4.0%	3.9%	4.0%	7.4%	-3.4%	-3.5%	-3.5%	
Last 12 Months	5.1%	3.7%	3.7%	13.3%	-8.1%	-9.6%	-9.6%	
Since Inception **	448.5%	371.9%	423.3%	361.5%	87.0%	10.4%	61.8%	
Compounded growth p.a.	13.6%	12.3%	13.2%	12.1%	1.5%	0.2%	1.1%	
Standard deviation	12.1%	12.2%	12.0%	12.8%				
Reward/Risk	1.12	1.01	1.10	0.94				
Tracking error	4.08							
Information ratio	0.28							
Best month	11.8%	11.8%	11.4%	11.6%				
Worst month	-7.9%	-8.2%	-8.1%	-8.1%				
Maximum drawdown	-25.4%	-25.9%	-25.2%	-27.0%				



\* MSCI World Healthcare Index USD

\*\* Since inception November 16th, 2010


\*\*\* All numbers as of March 27th, 2024 (due to bank holidays on March 28th-29th)

All performance figures from Sector Healthcare Value are net of fees

Class A USD	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
2024	0.9%	0.9%	2.1%										4.0%
2023	1.4%	-3.1%	2.4%	3.9%	-5.0%	4.4%	-0.2%	-2.5%	-3.5%	-4.9%	4.9%	4.8%	1.6%
2022	-3.3%	-0.2%	2.3%	-2.5%	1.0%	-3.1%	1.3%	-5.5%	-3.5%	8.8%	4.4%	-0.5%	-1.6%
2021	1.5%	-2.7%	3.2%	3.3%	1.9%	1.8%	1.0%	1.7%	-4.9%	2.5%	-4.4%	6.3%	11.2%
2020	-1.8%	-4.8%	-5.5%	11.8%	3.6%	-1.5%	3.4%	1.7%	-2.5%	-4.2%	7.2%	2.9%	9.3%
2019	7.4%	2.8%	0.7%	-1.9%	-4.3%	6.0%	0.4%	-0.8%	0.4%	4.0%	5.4%	3.0%	24.9%
2018	5.6%	-3.0%	-0.6%	1.6%	1.7%	1.5%	4.6%	3.0%	1.8%	-6.7%	4.2%	-7.9%	5.0%
2017	2.6%	5.1%	0.8%	2.5%	2.4%	2.9%	-0.3%	0.8%	1.6%	-2.0%	1.4%	-0.6%	18.4%
2016	-6.7%	-0.5%	3.9%	4.4%	2.9%	1.0%	4.8%	-3.1%	0.8%	-5.3%	0.3%	1.8%	3.7%
2015	1.7%	5.4%	2.2%	0.3%	2.6%	-0.1%	4.2%	-3.0%	-6.5%	6.5%	0.3%	1.7%	15.5%
2014	1.2%	6.2%	-1.0%	-0.1%	2.8%	1.8%	-0.7%	2.1%	0.4%	1.9%	2.9%	0.7%	19.5%
2013	8.6%	0.9%	4.3%	3.8%	1.7%	-0.5%	7.5%	-1.9%	3.1%	2.7%	4.5%	2.1%	43.0%
2012	3.6%	0.9%	4.4%	0.4%	-3.7%	6.8%	1.2%	1.7%	4.6%	-1.6%	1.6%	0.8%	22.2%
2011	0.2%	2.6%	0.9%	7.4%	2.9%	-2.6%	-3.0%	-3.1%	-4.4%	7.8%	-3.0%	2.1%	6.9%
2010											-1.7%	6.4%	4.6%

## Analysis of Risk

Exposure	96.7%	# of positions	44
----------	-------	----------------	----



## Fund Details

Fund Type	UCITS	Class	ISIN	Bloomberg Ticker
Fund Style	Actively managed	A USD	IE00B40JDW74	SECHVAU ID Equity
Fund Name	Sector Healthcare Value Fund, a sub-fund of Sector Capital Funds Plc	A EUR	IE00B0L26Q21	SECHVAE ID Equity
		A NOK	IE00B0L26Q21	SECHVAN ID Equity
Domicile	Ireland			
Portfolio Manager	Sector Gamma AS			
Inception Date	16 November 2010			
Liquidity	Daily			
Base Currency	USD			
Morningstar Rating (10 yrs)	★★★★★			

## Disclaimer

This information is intended for general information purposes only and does not constitute solicitation of or an offer to participate in any investment. This information does not, nor does it purport to, constitute any form of investment advice, recommendation or independent analysis. Consequently, it has not been prepared in accordance with the rules and regulations governing such publications, including but not limited to any prospectus requirements. This information is not, and does not purport to be, complete. The information is strictly confidential and should not be copied or circulated to anyone but the addressed recipients.

**This is a marketing communication.** The complete offering documents for the relevant investment fund should be read carefully and potential investors should seek independent investment advice and tax advice before making an investment. No assurance can be given that the stated investment objectives will be achieved, and the value of investments may fall as well as rise. This presentation contains historical performance for the presented investment funds. **Past performance does not predict future returns.** The investment managers, their directors, employees and consultants do not accept any form of liability (whether arising in contract, tort, negligence or otherwise) for any error, omission or similar misrepresentation in this general information or for any loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this information or any other person.

Investment in alternative investment fund(s) managed by the investment managers (the "AIFs") are solely for sophisticated investors who are (i) professional investors according to the Norwegian Alternative Investment Fund Managers Act or (ii) professional clients or eligible counterparties according to the Norwegian Securities Trading Act. The AIFs are unsuitable and unavailable for any person or entity not meeting such qualifications. Investment in the AIFs are intended for investors who can accept the risks associated with such an investment and who have no need for immediate liquidity in their investment. Investments will be subject to strict limitations on transferability and withdrawal. There will be no secondary or public market. The foregoing list of risk factors is not complete. If you are unsure as to whether you qualify, please contact the relevant investment manager.

Investment in UCITS fund(s) managed by the investment managers may be suitable for both non-professional and professional investors. On the website, you will find the latest updated information to investors, such as KIID documents and supplements.

We make no warranties that the material in this presentation is appropriate or available for use in countries other than Norway. Persons receiving this information are obliged to investigate whether there are any restrictions in their jurisdiction, and if so, to comply with any such restriction. The investment managers do not accept any responsibility for any failure to comply with any such restriction. For further information, please contact the relevant investment manager.

### ADDITIONAL INFORMATION FOR QUALIFIED INVESTORS IN SWITZERLAND

The state of the origin of the Fund is Ireland. In Switzerland, this document may only be provided to qualified investors within the meaning of art. 10 para. 3 and 3ter CISA. In Switzerland, both the representative agent and paying agent is Banque Héritage SA, Route de Chêne 61, 1211 Geneva 6, Switzerland. Investors in Switzerland can obtain documents of the funds, such as Confidential Information Memorandum and the financial reports free of charge from the Swiss representative. In Switzerland, Sector Capital AS promotes the acquisition and disposal of the Fund (FinSA Art. 3, letter c, paragraph 1.).

### ADDITIONAL INFORMATION FOR QUALIFIED AND APPLICABLE INVESTORS IN THE UNITED STATES

The interests in the fund(s) have not been, nor will they be, registered or qualified under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any applicable securities laws of any state or other political sub divisions of the United States, and may not be offered, sold, transferred or delivered, directly or indirectly, in the United States or to, or for the account or benefit of, any U.S. Person, except pursuant to an exemption from, or in a transaction not subject to the requirements of, the U.S. Securities Act and any applicable U.S. state securities laws. The fund(s) have not registered and do not intend to register under the U.S. Investment Company Act of 1940, as amended (the "Investment Company Act") in reliance on the exemption from such registration pursuant to Section 3(c)(7) thereunder and certain interpretations of Section 7(d) of the Investment Company Act by the staff of the U.S. Securities and Exchange Commission. Accordingly, the Interests are being offered and sold only: (i) outside the United States to persons other than U.S. Persons in offshore transactions that meet the requirements of Regulation S under the U.S. Securities Act; or (ii) to U.S. Persons who are (a) "accredited investors" as defined in Rule 501 of Regulation D promulgated under the U.S. Securities Act and (b) "qualified purchasers" within the meaning of Section 2(a)(51) of the Investment Company Act.

April 2024